From the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT (KH); College of Pharmacy, Department of Medicinal Chemistry, University of Florida, Gainesville, FL (OG); Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program (LP, DHE); and Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (KES).
J Addict Med. 2024;18(6):719-722. doi: 10.1097/ADM.0000000000001346. Epub 2024 Jul 16.
To estimate lifetime, past-year, and past-month prevalence of kratom, cannabis, and cannabidiol-only product use among adults 18 years and older in the United States, using 2 independent datasets.
Utilizing ( a ) the 2022 National Survey on Drug Use and Health (NSDUH) and ( b ) a 2022 online national convenience sample of adults who use kratom regularly (from our research group at the National Institute on Drug Abuse [NIDA]), we examined key demographic information as well as lifetime, past-year, and past-month substance use and preferences.
Among the full sample of adults from the 2022 NSDUH, the prevalence of lifetime use was 49.69% for cannabis, 34.09% for cannabidiol-only products, and 1.93% for kratom. When solely examining participants who have used kratom, both independent datasets showed higher proportions of cannabis use over the lifetime-92.81% (95% confidence interval: 90.31-95.31) in the NSDUH subset and 92.16% (95% confidence interval: 89.37-94.95) in our NIDA sample.
Our study demonstrates that people are co-using kratom with cannabis and/or cannabidiol-only products at the same time or during the same time period, though more research is needed to understand people's motivations and practices for such co-use. Co-use might result in herb-herb interactions that may impact research findings and clinical outcomes for people who use kratom.
利用美国 2 个独立数据集，估计 18 岁及以上成年人一生中、过去一年和过去一个月使用卡痛、大麻和大麻素产品的流行率。
利用（a）2022 年全国毒品使用与健康调查（NSDUH）和（b）我们在国家药物滥用研究所（NIDA）的一项针对经常使用卡痛的成年人的 2022 年在线全国便利样本，我们检查了关键的人口统计信息以及一生中、过去一年和过去一个月的物质使用和偏好。
在 2022 年 NSDUH 的成年人全样本中，大麻的终生使用率为 49.69%，大麻素产品的使用率为 34.09%，卡痛的使用率为 1.93%。当仅检查使用过卡痛的参与者时，两个独立数据集都显示出更高比例的一生中使用大麻-在 NSDUH 子集中为 92.81%（95%置信区间：90.31-95.31），在我们的 NIDA 样本中为 92.16%（95%置信区间：89.37-94.95）。
我们的研究表明，人们同时或在同一时期同时使用卡痛与大麻和/或大麻素产品，尽管需要更多的研究来了解人们共同使用的动机和做法。共同使用可能会导致草药-草药相互作用，这可能会影响使用卡痛的人的研究结果和临床结果。
